These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 9255148)

  • 1. Staging recurrent metastatic colorectal carcinoma with PET.
    Delbeke D; Vitola JV; Sandler MP; Arildsen RC; Powers TA; Wright JK; Chapman WC; Pinson CW
    J Nucl Med; 1997 Aug; 38(8):1196-201. PubMed ID: 9255148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver.
    Vitola JV; Delbeke D; Sandler MP; Campbell MG; Powers TA; Wright JK; Chapman WC; Pinson CW
    Am J Surg; 1996 Jan; 171(1):21-6. PubMed ID: 8554144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
    Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
    J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
    Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
    Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
    Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
    Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dual-time point images of the liver with (18)F-FDG PET/CT in suspected recurrence from colorectal cancer].
    Fuster D; Lafuente S; Setoain X; Navales I; Perissinotti A; Pavia J; Paredes P; Lomeña F; Pons F
    Rev Esp Med Nucl Imagen Mol; 2012; 31(3):111-6. PubMed ID: 22154291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.
    Boykin KN; Zibari GB; Lilien DL; McMillan RW; Aultman DF; McDonald JC
    Am Surg; 1999 Dec; 65(12):1183-5. PubMed ID: 10597072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
    Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
    J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
    Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
    Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?
    Selzner M; Hany TF; Wildbrett P; McCormack L; Kadry Z; Clavien PA
    Ann Surg; 2004 Dec; 240(6):1027-34; discussion 1035-6. PubMed ID: 15570208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors.
    Böhm B; Voth M; Geoghegan J; Hellfritzsch H; Petrovich A; Scheele J; Gottschild D
    J Cancer Res Clin Oncol; 2004 May; 130(5):266-72. PubMed ID: 14767761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT: will it change the way that we use CT in cancer imaging?
    Hicks RJ; Ware RE; Lau EW
    Cancer Imaging; 2006 Oct; 6(Spec No A):S52-62. PubMed ID: 17114079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver.
    Zhuang H; Sinha P; Pourdehnad M; Duarte PS; Yamamoto AJ; Alavi A
    Nucl Med Commun; 2000 Sep; 21(9):793-8. PubMed ID: 11065150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT?
    Ramos E; Valls C; Martinez L; Lladó L; Torras J; Ruiz S; Gamez C; Serrano T; Fabregat J; Rafecas A
    Ann Surg Oncol; 2011 Sep; 18(9):2654-61. PubMed ID: 21431987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of positron emission tomography in staging esophageal cancer.
    Luketich JD; Schauer PR; Meltzer CC; Landreneau RJ; Urso GK; Townsend DW; Ferson PF; Keenan RJ; Belani CP
    Ann Thorac Surg; 1997 Sep; 64(3):765-9. PubMed ID: 9307471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of chemotherapy on the impact of FDG-PET/CT in selection of patients for surgical resection of colorectal liver metastases: single center analysis of PET-CAM randomized trial.
    Metser U; Halankar J; Langer D; Mohan R; Hussey D; Hadas M; Tamir S
    Ann Nucl Med; 2017 Feb; 31(2):153-162. PubMed ID: 27848159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization.
    Vitola JV; Delbeke D; Meranze SG; Mazer MJ; Pinson CW
    Cancer; 1996 Nov; 78(10):2216-22. PubMed ID: 8918417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
    Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
    Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.